Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 86,1 M
EBIT 2017 -139 M
Net income 2017 -143 M
Finance 2017 42,0 M
Yield 2017 -
Sales 2018 125 M
EBIT 2018 -110 M
Net income 2018 -115 M
Finance 2018 28,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 11,5x
EV / Sales2018 8,01x
Capitalization 1 029 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the development of breakthrough treatments for human disease.It has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications.The company was... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
11/14 Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/08 LEXICON PHARMACEUTICALS : Management's Discussion and Analysis of Financial Cond..
11/08 LEXICON PHARMACEUTICALS, INC. (NASDA : LXRX) Files An 8-K Results of Operations ..
11/08 LEXICON PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (f..
11/08 LEXICON PHARMACEUTICALS : reports 3Q loss
11/08 LEXICON PHARMACEUTICALS : to Present at Upcoming Investor Conferences
10/05 LEXICON PHARMACEUTICALS : Initiates Patient Dosing In A Phase 1 Study Of LX9211
10/04 LEXICON PHARMACEUTICALS : 65IB) Award Effective 9/30/2017 65IB Drugs, Pharmaceut..
10/04 LEXICON PHARMACEUTICALS : 65-- Lexicon Pharmaceuticals, Inc (65IB) Award Effecti..
10/04 LEXICON PHARMACEUTICALS : $2.83 Million Federal Contract Awarded to Lexicon Phar..
More news
Sector news : Bio Therapeutic Drugs
09:31aDJBAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 25,8 $
Spread / Average Target 165%
EPS Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
Frank P. Palantoni Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICALS, INC.12.10%1 029
GILEAD SCIENCES1.69%95 098
REGENERON PHARMACEUTICALS5.57%41 637
VERTEX PHARMACEUTICALS99.59%37 187
GENMAB2.13%11 669
EXELIXIS, INC.75.25%7 731